Drug Discovery World

JULY 19, 2024

Biotechnology company Draupnir Bio has received equity investments totalling €12 million to support the company’s work in the field of targeted protein degradation (TPD).

Targeted Protein Degradation 130

Targeted Protein Degradation Small Molecule Research Government 130

BMG Labtech

APRIL 16, 2024

Promising future Molecular glues offer exciting opportunities for targeted protein degradation and new ways to reach some of the estimated 85% of undruggable targets in the proteome. Conventional drug development has often focused on finding small molecules that fit the active site of a protein.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Drug Development Disease 40

Drug Discovery World

OCTOBER 16, 2023

Professor Henrik Daub , Founder and CSO, NEOsphere Biotechnologies looks at the advancements taking place in proteomics and how targeted protein degradation represents a promising approach for developing new treatments for life-threatening diseases.

Targeted Protein Degradation 147

Targeted Protein Degradation Small Molecule Molecular Biology Treatment 147

Drug Discovery World

MARCH 22, 2023

Oxford Drug Design and PhoreMost advance novel cancer therapeutics Oxford Drug Design has been engaged by PhoreMost to accelerate a targeted protein degradation discovery programme for novel cancer therapeutics.

Targeted Protein Degradation 130

Targeted Protein Degradation Drugs Small Molecule Licensing 130

Drug Discovery World

APRIL 6, 2023

These topics will be represented across a range of session types, including methods workshops, minisymposia, poster and plenary sessions, as well as keynotes, awards and lectures.

Small Molecule 130

Small Molecule Targeted Protein Degradation Clinical Trials Engineering 130

Drug Discovery World

MAY 11, 2023

However, she also presented thoughts in a technical update, Targeted Protein Degradation – Progress, Direction and Prospects. At previous events, there has been an air of excitement but uncertainty of how quickly to adopt ‘business as usual’. This uncertainty seems to be a thing of the past, if BioTrinity is anything to go by.

Targeted Protein Degradation 130

Targeted Protein Degradation Science Small Molecule Vaccine 130

Drug Discovery World

OCTOBER 16, 2023

A company within this ecosystem is STORM Therapeutics, a clinical stage biotechnology company creating novel small molecule therapies that inhibit RNA modifying enzymes (RME) for use in oncology and other diseases.

Drugs 189

Drugs Science Therapies Targeted Protein Degradation 189